In the future, NGS-based genome-wide analyses, which have limited applicability for mutation calling of cMS, such as TGFBR2 in individual tumors [45,68], but are superior in detecting general, genome-wide effects, are warranted to quantitatively confirm cMS mutation loads in incident CRC. This evidence concerns the gene TGFBR2 and colorectal carcinoma.